Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: Mar 31, 2025
Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled
Read more at globenewswire.comNASDAQ:FBIO (8/18/2025, 10:27:09 AM)
2.23
+0.11 (+5.19%)
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP
NASDAQ:FBIOP (8/18/2025, 10:15:18 AM)
7.77
-0.11 (-1.4%)
Find more stocks in the Stock Screener
